multitargeted combination therapiesfibroblast growth factor-21 analoguesdiacylglycerol O-acyltransferase 2 inhibitorsthyroid hormone receptor-beta (THR-β) agonistsperoxisome proliferator-activated receptor agonistsglucagon-like peptide-1 (GLP-1) receptor agonistsMetabolic dysfunction-associated steatohepatitisTHR-β agonistsacetyl-CoA carboxylase (ACC) inhibitorsMASH
…nd systemic metabolic parameters, prompting growing interest in multitargeted combination therapies. Multitargeted and combination strategies for MASH can modulate…